<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-HJSZOYKU</identifier><date>2020</date><creator>Mangaroski, Dushan</creator><creator>Škof, Erik</creator><relation>documents/doc/H/URN_NBN_SI_doc-HJSZOYKU_001.pdf</relation><relation>documents/doc/H/URN_NBN_SI_doc-HJSZOYKU_001.txt</relation><format format_type="issue">1</format><format format_type="volume">24</format><format format_type="type">article</format><format format_type="extent">str. 20-24</format><identifier identifier_type="ISSN">1408-1741</identifier><identifier identifier_type="COBISSID_HOST">24701955</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-HJSZOYKU</identifier><language>slv</language><publisher>Onkološki inštitut Ljubljana</publisher><source>Onkologija (Ljubljana)</source><rights>BY</rights><subject language_type_id="slv">bevacizumab</subject><subject language_type_id="slv">epitelijski rak</subject><subject language_type_id="slv">kemoterapija</subject><subject language_type_id="slv">rak jajčnikov</subject><title>Naše izkušnje z zdravilom bevacizumab v primarnem zdravljenju epitelijskega raka jajčnikov</title><title>Our experience with bevacizumab in the primary treatment of epithelial ovarian cancer</title></Record>